These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38393054)

  • 1. Identification of PLK1-PBD Inhibitors from the Library of Marine Natural Products: 3D QSAR Pharmacophore, ADMET, Scaffold Hopping, Molecular Docking, and Molecular Dynamics Study.
    Zhou N; Zheng C; Tan H; Luo L
    Mar Drugs; 2024 Feb; 22(2):. PubMed ID: 38393054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking.
    Luo L; Tan H; Liao Y
    J Biomol Struct Dyn; 2023; 41(22):13180-13197. PubMed ID: 36856049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
    Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
    Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
    Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
    J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products.
    Luo L; Zhong A; Wang Q; Zheng T
    Mar Drugs; 2021 Dec; 20(1):. PubMed ID: 35049884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
    Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
    PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Inhibitors of CDK4/6 from a Library of Marine Compound Database: A Pharmacophore, ADMET, Molecular Docking and Molecular Dynamics Study.
    Luo L; Wang Q; Liao Y
    Mar Drugs; 2022 May; 20(5):. PubMed ID: 35621970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
    Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
    J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors.
    Lu S; Liu HC; Chen YD; Yuan HL; Sun SL; Gao YP; Yang P; Zhang L; Lu T
    Int J Mol Sci; 2011; 12(12):8713-39. PubMed ID: 22272100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided Design and Optimization of small Molecules as Pancreatic Lipase Inhibitors using Pharmacophore, 3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation Studies.
    Modanwal S; Mulpuru V; Mishra N
    Curr Comput Aided Drug Des; 2023; 19(4):258-277. PubMed ID: 36597611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain.
    Olawale F; Iwaloye O; Elekofehinti OO
    J Biomol Struct Dyn; 2022; 40(24):13606-13624. PubMed ID: 34669551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
    Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
    J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
    Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
    J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation.
    Verma H; Narendra G; Raju B; Kumar M; Jain SK; Tung GK; Singh PK; Silakari O
    Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200108. PubMed ID: 35618489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying natural products for gastric cancer treatment through pharmacophore creation, 3D QSAR, virtual screening, and molecular dynamics studies.
    Jalali Z; Nejad Ebrahimi S; Rezadoost H
    Daru; 2023 Dec; 31(2):243-258. PubMed ID: 37733194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.
    Zhou Y; Yan F; Huo X; Niu MM
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.
    Ren JX; Li CP; Zhou XL; Cao XS; Xie Y
    J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.